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1. Introduction 
The use of complementary and alternative medicine (CAM) is increasing in children with 
chronic illness or disability (Mamtani&Cimino 2002; Ernst 2005; Hyman&Levy 2005; 
Sinha&Efron 2005). Generally, the term CAM includes complementary therapies, such as 
behavioural/physical therapies, in addition to products such as herbals and vitamins that 
are administered systemically. This study specifically considers CAM products and 
supplements. Prevalence of biologically-based CAM product use in children with autism 
spectrum disorder (ASD) is among the highest of any population, with reported lifetime use 
of between 35% and 70% (Hanson et al. 2007; Christon et al. 2010; Green et al. 2006; Senel 
2010). High CAM usage in autism has been attributed to the availability of few conventional 
pharmacological treatments  that have a limited evidence base and are often associated with 
significant adverse effects.  
Recent well-designed studies using whole-genome scanning methods, cytogenetics and 
genetic linkage/association analyses indicate genetic factors play a key role in the aetiology of 
autism (Eapen, 2011).  Environmental and epigenetic factors have also been shown to impact 
on susceptibility to autism (Persico&Bourgeron 2006). Evidence is building that autism 
represents a cluster of syndromes that have distinct aetiologies involving inflammation, 
increased oxidative stress, impaired gastrointestinal (GI) health, mitochondrial dysfunction, 
autoimmune processes, and impaired ability to neutralise toxins (London 2007).  
There is a belief that CAM products may ameliorate biological abnormalities that are 
reported to occur in autism. Reasons cited by parents for using CAM products for their 
children with autism include general health maintenance as well as specific symptoms such 
as  moodiness, aggression, irritability, hyperactivity, inattention, GI symptoms, and sleep 
difficulties (Wong&Smith 2006). Another reason commonly cited by caregivers for 
implementing CAM products is that sensory processing difficulties and aberrant behaviour 
that can occur in children with autism may lead to poor feeding patterns and the possibility 
of nutritional deficiencies (Geraghty et al. 2010).  
A study by Golnik and Ireland (2009) surveyed 539 medical practitioners (19% response rate 
using email and regular post) regarding CAM use in children with autism. The study 
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revealed physicians encouraged use of multi-vitamins (49%), PUFAs (25%), melatonin (25%) 
and probiotics (19%) in children with autism and discouraged use of chelation (61%) and 
secretin (43%). In the same study medical practitioners responded positively when asked if 
they desired more complementary alternative medicine training for these patients 
(Golnik&Ireland 2009). 
Despite this widespread use of CAM products in children with autism, it is of concern that 
there is a distinct lack of accurate, unbiased and evidence-based information about CAMs 
available for health professionals and caregivers of children with autism. Ready access to 
information through the Internet has contributed to the general increased frequency of 
caregivers implementing CAMs (Hyman&Levy 2005). Families perceive CAMs as a risk-free 
approach that may improve their child’s outcome (Hyman&Levy 2005). However, all 
treatments used in children should be judged on standards of scientific research 
(Levy&Hyman 2003).  Studies supporting CAM usage in autism need to be evaluated for 
scientific study design, clinical safety and scientific validity (Levy&Hyman 2003). There 
have been few published reviews examining the evidence for rationale, safety and efficacy 
of CAM products in autism (Angley et al. 2007; Weber&Newmark 2007; Levy&Hyman 2008; 
Atkins et al. 2010),  and none were conducted systematically. To address this gap, we have 
endeavoured to address this area systematically in this chapter. 
This chapter presents the first part of a two-part review. The rationale for a range of CAM 
products that are used in the management of autism is examined in this chapter. It is hoped 
this information will inform researchers and health care professionals about the theoretical 
or proven basis for a range of CAM products used in autism. 
Chapter 4 which is the second part of the two-part review includes an examination of the 
evidence for efficacy and safety of a range of CAM products in autism. Each CAM product 
for which randomised controlled trials have been conducted has been assigned to a category 
of the Natural Standard Research Collaboration grading rationale for efficacy (Natural 
Standard Research Collaboration 2010). To determine safety of the range of CAM products 
investigated, all types of trials where a specific CAM product has been investigated in 
autism have been examined. 
2. Aim 
To systematically review the literature to determine the rationale of a range of CAM 
products used in ASD. Specifically, the following interventions were investigated: vitamins 
A, B, C and E, dimethylglycine (DMG), calcium, iron, magnesium, selenium, zinc, 
probiotics, digestive enzymes, colostrum, secretin,  olive leaf extract, polyunsaturated fatty 
acids (PUFAs), melatonin, chelating agents (dimercaptosuccinic acid and thiamine 
tetrahydrofuryl disulphide), metallothionein promotion, glutathione and glutamine.   
3. Method 
For part 1 of this 2-part review (i.e. Chapter 3), a generalised review of the literature was 
performed to examine the possible rationale behind the use of these CAMs in ASD which 
included locating articles describing and investigating the biological basis of autism. Cross-
sectional studies investigating biochemical abnormalities that occur in autism were also 
retrieved. For part 2, (i.e. Chapter 4) randomised controlled trials or randomised cross-over   
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Topic Search Terms 
Calcium Calcium/, calcium.mp, bone meal.mp 
Chelation/Allithiamine/TTFD/DMSA 
chelating agent$.mp, ttfd.mp, tetrahydrofurfuryl 
disulfide.mp, allithiamine.mp, Chelating Agents/, 
Chelation Therapy/, Thiamine/, Garlic/ 
dimercaptosuccinic acid.mp, dmsa.mp 
Colostrum colostrum.mp, Colostrum/ 
Dimethylglycine dimethylglycine.mp, DMG.mp 
Enzyme therapy Enzymes/, Peptide hydrolases/, Pancrelipase/, 
Lipase/, Amylases/, gastrointestinal agents/, 
proteolytic enzyme$.mp., enzyme$.mp., pancreatic 
enzyme$.mp., enzyme therapy.mp., carboxyl 
peptidase.mp., 
Fatty acids  Fatty Acids, Essential/, Fish Oils/, 
Docosahexaenoic Acids/, Fatty Acids, Omega-3/, 
Cod Liver Oil/, Fatty Acids, Unsaturated/, 
Eicosapentaenoic Acid/ Fatty Acids, Omega-6/, 
gamma-Linolenic Acid/, Linoleic Acid/, Evening 
Primrose/, Onagraceae/, Oenothera/, essential 
fatty acid.mp, fish oil.mp, docosahexaenoic 
acid.mp, omega 3.mp, w-3 fatty acid.mp, cod liver 
oil.mp, marine oil.mp, menhaden oil.mp, highly 
unsaturated fatty acid.mp, eicosapentaenoic 
acid.mp, evening primrose oil.mp, fever plant.mp, 
gamma linolenic acid.mp, linoleic acid.mp, night 




Iron/, Ferrous Compounds/, iron.mp, ferrous$.mp. 
L-glutamine Glutamine/, l-glutamine.mp, glutamine.mp 
Magnesium 
Magnesium/, Magnesium Compounds, 
magnesium.mp.  
Melatonin Melatonin/, melatonin.mp 
Metallothionein 
metallothionein.mp, mt promoter.mp, 
metallothionein promoter.mp, Metallothionein/ 
Olive leaf extract 
Olea/, Olive/, olive lea$.mp., olea.mp., 
oleuropein.mp., olea europaea.mp. 
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Topic Search Terms 
Probiotics 
Probiotics/, Probiotic/, Yogurt/, Lactobacillus/, 
Bifidobacterium/, probiotic$.mp., yeast.mp., 





reduced glutathione.mp, glutathione.mp, 
Glutathione/ 
Selenium Selenium.mp, Selenium/, Selenium Compounds 
Secretin Secretin/, secretin.mp 
Vitamins Vitamin A/, Retinoids/, vitamin A.mp, retino$.mp, 
Fat-soluble vitamin$.mp, water soluble 
vitamin$.mp., Ascorbic Acid/, vitamin B6.mp, 
pyridoxine.mp, Vitamin B 6/, Pyridoxine/, Vitamin 
B 6 deficiency/, folic acid.mp, folinic acid.mp, 
folate.mp, vitamin B9.mp, Folic Acid/, 
Leucovorin/, Folic Acid Deficiency/, Vitamin B 
Complex/, vitamin B12.mp, cyanocobalamin.mp, 
methylcobalamin.mp, Vitamin B 12/, vitamin 
C.mp, ascorbic acid.mp, ascorbate.mp, 
ascorbyl$.mp. Vitamin E/, Tocopherols/, 
Tocotrienols/, vitamin E.mp, tocopherol.mp, 
tocotrienol.mp. 
Zinc zinc.mp, Zn.mp, Zinc/ 
/ at the end of a term denotes a subject heading in MEDLINE, AMED or CINAHL. Some subject 
headings differ between these databases. 
In some databases the symbol $ is used to truncate a word, in some databases the symbol * is used instead 
Table 1. Search terms used in database searches. 
trials in which participants served as their own controls, were used to assess effectiveness of 
specific CAMs in individuals with ASD. Clinical trials of all designs were used to examine 
reported adverse effects of the CAMs in this population. 
For the purposes of this review, the term CAM was used only in reference to non-
conventional medications, sometimes termed ‘biological treatments’ or ‘dietary 
supplements’ (Levy&Hyman 2005) used in ASD, but not other forms of complementary or 
alternative therapy (e.g. touch therapies, manipulation therapies). Off-label use of 
prescription medications was not considered in this review. 
The list of CAM products selected for review was developed using previous literature 
reporting CAM products being implemented by caregivers in their children with autism 
(Green et al. 2006; Wong&Smith 2006; Hanson et al. 2007; Christon et al. 2010) and 
consensus amongst authors based on our own research experiences. 
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Computerised literature searches were performed to locate articles reporting  clinical trials 
of CAMs in children or adults with ASD. The databases searched were Medline (via Ovid), 
EMBASE, International Pharmaceutical Abstracts (IPA), Allied and Complementary 
Medicine (AMED), CINAHL, the Natural Medicines Comprehensive Database (Therapeutic 
Research Faculty) and The Cochrane Library. 
To search for articles relevant to ASD standardised search terms were used including: 
autis$.mp, Asperger$.mp, developmental disabilit$.mp, pervasive developmental 
disorder$.mp (as key words); and Autistic Disorder/, Asperger Syndrome/, Child 
Development Disorders/, Developmental Disabilities/, Speech Disorders/, Child 
Psychiatry/ Communication Disorders/, Language Disorders (as subject headings). 
These terms were combined with other terms to identify articles on specific CAMs as 
indicated in Table 1. Studies were restricted to English language. Searches were restricted to 
the years 1970 to December 2010. The reference lists of published studies and systematic 
reviews were also checked for relevant articles.  
For the Natural Medicines Comprehensive Database the Product Effectiveness Checker was 
used to search for articles examining effectiveness for autism or Asperger Syndrome. 
4. Results 
4.1 Rationale 
CAM product usage in autism generally has a theoretical basis rather than a proven 
rationale.  However, there are some instances where biochemical abnormalities have been 
demonstrated in studies which can be normalised with administration of CAM products. 
For example James et al. (2004) showed biomarkers of oxidative stress in children with 
autism could be normalised following supplementation with  betaine, folinic acid and 
vitamin B12. Some studies have also examined how the effects of biochemical normalisation 
translate into quantifiable outcome measures of behaviour in autism.  
The rationale for the use of the CAM products investigated was found to fall into one or 
more of the following categories: promote GI health, reduce oxidative stress, enhance 
detoxification of heavy metals,  modulate the immune system, normalise neurotransmitter 
abnormalities, promote sleep and prevent or treat nutritional deficiencies. The theoretical or 
proven abnormality occurring in autism, rationale for the CAM products investigated and 
behaviour targeted where known are summarised in Table 2. 
4.1.1 Promotion of gastrointestinal health 
A high frequency of GI disturbance occurring in individuals with autism was first 
reported almost 40 years ago (Goodwin et al. 1971),  but data regarding prevalence are 
conflicting. High rates of functional gastrointestinal disorders (FGIDs)  in individuals 
with ASD have been reported in several studies including abdominal pain, constipation, 
diarrhoea, diarrhoea and alternating constipation and GI inflammation (Horvath et al. 
1999; Molloy&Manning-Courtney 2003; Levy et al. 2007). A prospective study by 
Valicenti-McDermott et al. reported an increased prevalence of GI conditions in children 
with ASD (n=50, 70%) compared with matched controls that included both neurotypical 
children (n=50, 28%) and those with non-ASD developmental disorders (n=50, 42%) 
(2006). However, a recent well-designed population-based study by Ibrahim et al. found 
that the overall incidence of GI symptoms did not differ between cases of autism and 
controls (2009).  
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Recently Campbell et al. have provided genetic evidence supporting the link between GI 
dysfunction and autism and reported an association between a single nucleotide 
polymorphism in the promoter of the mesenchymal epithelial transition (MET) factor gene 
and autism (2009). Evidence is also emerging that intestinal permeability (D'Eufemia et al. 
1996; Horvath et al. 1999; de Magistris et al. 2010), GI mucosal inflammation (de Magistris et 
al. 2010), fermentation products (Yap et al. 2010) and GI microbiota profiles  (Finegold et al. 
2002; Song et al. 2004; Parracho et al. 2005; Finegold et al. 2010) in individuals with autism 
are different from those of the general population.  
4.1.1.1 Intestinal hyper-permeability in autism 
Functional changes have been reported in the GI tracts of children with autism including 
increased intestinal permeability (Horvath&Perman 2002). Intestinal permeability, as 
measured by the urinary excretion of metabolically inert sugars, is a surrogate marker of  
mucosal integrity and gut barrier function (de Magistris et al. 2010).  It has been 
hypothesised that impaired GI function may not only be a symptom of autism but may also 
contribute to the phenotypic presentation by increasing absorption of chemicals from the GI 
tract. There is a body of thought that increased absorption of opioid-like peptides that are 
derived from gluten and casein (i.e. the ‘opioid excess theory’) may disturb neurological 
function, as may GI overgrowth of neurotoxin-producing bacteria (Shattock&Whiteley 
2002).  
4.1.1.2 Altered gut fermentation products in autism 
A growing appreciation for the role of intestinal microflora in health and disease has 
emerged over the last few years, however the beneficial and potentially adverse 
contributions of bacterial fermentation by-products have not been well established and are 
largely uncharacterised in children with ASD. A recent metabonomic study revealed 
metabolic phenotype (metabotype) differences were observed between autistic and control 
children, which were associated with perturbations in the relative patterns of urinary 
mammalian microbial co-metabolites including dimethylamine, hippurate, and 
phenyacetylglutamine (Yap  et al. 2010).  Another study by Altieri et al. (2011) found higher 
levels of p-cresol in  urine of young children with autism than controls and also reported a 
positive correlation between urinary p-cresol and autism severity. P-cresol is a toxic 
metabolite of tyrosine catabolism by gut bacteria such as clostridial species and Pseudomonas 
stutzeri (Altieri et al. 2011). Whether the observed differences in urinary metabolites 
observed contribute to, or reflect, GI dysfunction in individuals with ASD requires further 
investigation.  
4.1.1.3 Altered GI microbiota profiles in autism 
Several studies have found some bacterial species, particularly some Clostridium species, are 
present in higher numbers in children with autism experiencing GI disturbance  (Finegold et 
al. 2002; Song et al. 2004; Parracho et al. 2005; Finegold et al. 2010). Some workers have 
speculated that the differences in the GI microbiotica could be contributing to the 
pathophysiology of ASD (Bolte 1998; Finegold 2008).  
4.1.1.4 Altered digestive enzyme capacity in autism 
It has been hypothesised that digestion of dietary gluten and casein in the small intestine by 
pancreatic and intestinal peptidases releases short chain peptide molecules (exorphins) 
which are structurally similar to endogenous opioid substances (White 2003). Other 
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hypotheses suggest that excessive opioid activity linked with dietary peptides from gluten 
and casein have an aetiological role in the pathogenesis of autism (Reichelt&Knivsberg 
2003).  The ‘opioid excess’ theory of autism proposes that many of the behaviours found in 
individuals with ASD mimic the influence of opioids on human brain function (White 2003).  
In addition Horvath & Perman (2002) demonstrated that 44 of 90 (49%) of children with 
autism showed at least one deficient disaccharidase enzyme activity. Lactase and maltase 
were the enzymes most commonly measured to have deficient activity, followed by sucrase, 
palatinase and glucoamylase. They found that all of the children with reduced enzyme 
activity had flatulence and/or loose stools. It is hypothesised that disaccharide 
malabsorption may cause chronic diarrhoea and flatulence in children with ASD and may 
contribute to abnormal behaviour (Patel et al. 2002). Hence, supplementation with these 
enzymes may cause a reduction in autism related symptoms. For example supplementation 
with lactase may resolve the symptoms related to lactose malabsorption (Horvath&Perman 
2002). 
It is speculated that GI symptoms exacerbate the behavioural manifestations of autism 
contributing to the severity of the disorder (Buie et al. 2010). Abdominal pain, constipation, 
and/or diarrhoea are unpleasant and can be painful and likely to produce frustration, 
behavioural problems, and possibly sleep disturbance, aggression and self abuse, especially 
in children unable to communicate their discomfort.  
Various CAMs are used to ameliorate the GI symptoms in children with autism as outlined 
in Table 2. Probiotics and prebiotics are used to promote gut health. Dietary interventions 
include the exclusion of gluten and casein containing foods together with dietary 
supplementation with peptidase enzymes. Peptidase enzymes are implemented in children 
with autism in an attempt to remove the opioid-like peptides that may exert a neurotoxic 
effect on the brain (Brudnak et al. 2002).  Less obvious candidates are PUFAs which are used 
with the rationale that they can decrease GI inflammation and improve a 'leaky gut'.  
4.1.2 Oxidative stress 
A leading theory implicated in the aetiology of autism is oxidative stress, which results from 
a complex interplay of genetic and environmental factors. Oxidative stress occurs when 
reactive oxygen species (ROS) levels exceed the antioxidant capacity of a cell leading to 
damage and functional impairment (McGinnis 2004). “It is thought that autism could result 
from an interaction between genetic and environmental factors with oxidative stress as a 
potential mechanism linking the two” (Ming et al. 2005, p.379). These ROS target lipids, 
proteins and nucleic acids (Chauhan&Chauhan 2006) resulting in a risk of neurologic 
deficits, especially during early life (Zecavati&Spence 2009). A range of evidence has 
emerged in recent years supporting the role of oxidative stress in the aetiology of autism.  
4.1.2.1 Lipid peroxidation 
It has also been found that lipid peroxidation (an oxidative biomarker) in plasma is 
significantly increased in children with autism when compared to their non-autistic siblings 
reflecting increased oxidative stress in autism (Chauhan et al. 2004).  
4.1.2.2 Antioxidants 
Reduced endogenous antioxidant capacity i.e. low levels of the plasma antioxidant enzymes 
glutathione peroxidase and superoxide dismutase have been found in autistic individuals 
(Sogut et al. 2003). Furthermore, Yorbik et al. (2002) found that the activities of erythrocyte 
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superoxide dismutase and erythrocyte and plasma glutathione peroxidase were 
significantly lower in 45 autistic children compared with 41 controls. Chauhan et al. (2004) 
also found a significant reduction of the major endogenous antioxidants transferrin and 
ceroplasmin in the serum of children with autism as compared to their typically developing 
siblings. An excess of toxic free radicals e.g. nitric oxide has also been reported in children 
with autism as compared to age and sex matched controls (Sogut et al. 2003). Ming et al. 
(2005) also describe increased nitrite concentrations, thiobarbituric acid reactive substances 
and xanthine oxidase activity in red blood cells in children with autism compared to 
controls. Notably, decreased plasma levels of the antioxidant vitamins A, C and E were 
reported in the same autistic cohort (Ming  et al. 2005).  
4.1.2.3 Mitochondrial disease 
Mitochondria serve a primary role in energy production during normal physiological 
function and generate high levels of ROS which are normally neutralised by free radical 
scavengers. In the event there is excess ROS relative to the antioxidant defence, 
mitochondrial dysfunction occurs exacerbating oxidative stress. Mitochondrial disease is 
associated with impaired neurodevelopment. Two recent studies have reported 
mitochondrial dysfunction in autism. Post-mortem samples showed increased 
mitochondrial metabolism and oxidised mitochondrial proteins in the brains of six people 
with autism compared with controls (Palmieri et al. 2010). Another study showed that 11/21 
patients with ASD had definite mitochondrial disease while the rest had probable 
mitochondrial disease (Weissman et al. 2008). 
4.1.2.4 Abnormalities in the trans-methylation and trans-sulphuration pathways 
There is emerging evidence that a deficient trans-methylation (i.e. folate/methionine) pathway 
has a role in the aetiology of autism (Boris et al. 2004; James et al. 2004; James et al. 2006). The 
folate/methionine pathway (Figure 1) is responsible for the synthesis of the deoxynucleotide 
triphosphate (dNTP) pools required for DNA synthesis and repair, the establishment and 
maintenance of stable DNA methylation patterns for tissue-specific gene expression and 
chromatin conformation and maintenance of the redox balance within each cell. 
As shown in Figure 1, the methionine cycle involves the re-methylation of homocysteine to 
methionine either by methionine synthase (MS) which is folate and vitamin B12 dependent 
or by the betaine homocysteine methyltransferase (BHMT) reaction.  The methyl group is 
donated by 5-methyl tetrahydrofolate synthesised by methylene tetrahydrofolate (MTHFR) 
from 5,10 methyl tetrahydrofolate. 
Methionine is activated by methionine adenosyl transferase (MAT) to S-adenosyl-methinine 
(SAM), the major methyl donor for cellular methyltransferase reactions (MTases).  
Following methyl transfer, SAM is converted to S-adenosylhomocysteine (SAH).  This is 
further metabolised in a reversible reaction to homocysteine and adenosine.  Adenosine is 
either phosphorylated to adenosine nucleotides by adenosine kinase (AK) or catabolised to 
inosine by adenosine deaminase (ADA).  Homocysteine may be permanently removed from 
the methionine cycle by irreversible conversion to cystathionine by cystathione-β-synthase 
(CßS).  Cystathionine is converted to cysteine which is the rate-limiting amino acid for the 
synthesis of glutathione. 
A decrease in turnover of the folate/methionine pathway will lead to decreased synthesis of 
SAM which is vital for normal methylation activity and decreased synthesis of cysteine and 
glutathione required for normal antioxidant activity.   
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Metabolites THF: tetrahydrofolate; SAM: S-adenosyl-methionine; SAH: S-adenosyl-homocysteine; 
GSH: reduced active glutathione; GSSG: oxidised disulfide form of glutathione 
Enzymes MS: methionine synthase; BHMT : Betaine homocysteine methyltransferase;  MAT: 
methionine adenosyl transferase; SAHH: SAH hydroxylase; CßS: Cystathione-β-synthase; CL: 
Cystathione lyase; MTHFR: methylene-tetra-hydrofolate reductase; MTRR: methionine synthase 
reductase 
Fig. 1. Folate cycle and the trans-methylation and trans-sulphuration pathways 
A systematic literature review identifying studies reporting metabolites, co-factors or genes 
of the folate/methionine pathway in autism found there are significant differences in the 
levels of various metabolites of the methionine/folate cycle in individuals with autism 
compared with controls although there are some inconsistencies between studies which may 
be due to different methodologies (Main et al. 2010).  
Elevated levels of oxidised GSH and subsequent reduction in GSH:GSSG ratio together with 
a decrease in cysteine (a rate limiting amino acid for glutathione synthesis) and increased 
lipid peroxidation suggests that oxidative stress may play a significant role in the aetiology 
of autism (James et al. 2004; Wu et al. 2004). The conclusion of  a review of oxidative 
pathways as potential drug targets in autism by Villagonzalo et al. (2010) was that although 
there is significant evidence demonstrating that oxidative pathways are disturbed in autism, 
there is insufficient evidence to decide whether oxidative stress is the cause of autism, or 
contributes to the illness, or is simply a consequence of the illness. They stated that further 
research is required to determine if children will benefit from antioxidant treatment and that 
longitudinal studies exploring oxidative biomarkers and autism symptomatology over time 
may be a methodology for investigation. 
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Thus as outlined in Table 2, oxidative stress in autism provides a rationale for the use of 
CAM products that are antioxidants in their own right, metabolites or co-factors of the 
trans-methylation or trans-sulphuration pathways, co-factors of plasma antioxidant 
enzymes and include: vitamins A, C & E, vitamin B12, DMG, magnesium, selenium, zinc, 
melatonin and glutathione. 
4.1.3 Heavy metal toxicity  
Heavy metals, such as arsenic, lead, and mercury have been associated with a variety of 
neurologic deficits and disorders, including lower IQ, Alzheimer’s disease, and Parkinson’s 
disease (Zecavati&Spence 2009). It has been suggested that some children with autism have 
an increased body-burden of mercury which may result from biochemical and genomic 
susceptibilities within detoxification pathways (Mutter et al. 2005).  
As mentioned above James et al. (2004) found a significantly reduced GSH: GSSG ratio in 
children with autism compared with controls. An impaired glutathione redox ratio is 
thought to play a role in the aetiology of autism by delaying the clearance of heavy metals 
from the body (Deth et al. 2008). The association between heavy metal exposure and autism, 
in particular mercury, has attracted considerable interest (Counter et al. 2002; Holmes et al. 
2003; Palmer et al. 2006; Geier&Geier 2007). Mercury has been implicated in immune, 
sensory, neurological, motor, and behavioural dysfunction resulting in clinical 
manifestations similar to those defining or associated with autism. Some studies have 
suggested that mercury can disrupt neurotransmitter levels and biochemistry (Faustman et 
al. 2000; Redwood et al. 2001; Bernard et al. 2002) and impact on normal child development. 
A suspected source of mercury is thiomersal, a preservative used in vaccines. Notably, 
although thiomersal has not been included in US vaccines since 2000, autism prevalence 
rates have continued to rise (Fombonne 2008).  
As shown in Table 2, CAM products that are implemented based on the rationale that 
autism is associated with heavy metal toxicity include probiotics, allithiamine/TTFD, 
DMSA, metallothionein promoter, glutathione and glutamine. 
4.1.4 Immune dysregulation in autism 
There is evidence to suggest the immune system plays a role in the aetiology of autism 
(Kidd 2002a). It is hypothesised that some cases of autism are associated with immune 
factors and that autism related symptoms may be associated with immune deficiencies or 
autoimmunity (Levy&Hyman 2005). Immunological anomalies involving cytokines, 
immunoglobulins, inflammation, and cellular activation have been reported in individuals 
with autism (Goines&Van de Water 2010). 
4.1.4.1 Immune deficiencies and autism 
Immune deficiencies in children with ASD have been reported due to frequently 
encountered medical problems including recurrent ear infection/rhinosinusitis/upper 
respiratory tract infection, adverse reactions to multiple medications, allergies, GI problems 
and prolonged courses of illness as compared to typically developing siblings (Jyonouchi et 
al. 2005; Levy&Hyman 2005). Various immune system deficits including abnormalities in 
cell-mediated immunity have been reported in autism. Abnormalities of macrophages, B 
cells, T cells and natural killer cells have been reported in individuals with ASD which may 
compromise defence against infection (Gupta 2000). 
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4.1.4.2 Autoimmune disease and autism 
A survey administered to families of 61 children with autism and 46 control families with 
typically developing children discovered that the mean number of autoimmune disorders 
was greater in families who had children with autism (Comi et al. 1999). In this study, Comi 
et al. (1999) found that 46% of the families of children with autism had two or more family 
members with autoimmune disorders (e.g. type 1 diabetes, adult rheumatoid arthritis and 
hypothyroidism). In addition, this finding may further suggest that genetic predisposition 
plays an important role in autism. However, Micali, Chakrabarti & Fombonne (2004) did not 
have the same findings following administration of a semi-structured questionnaire to 79 
parents of children with pervasive developmental disorders (PDDs) and 61 controls (parents 
with typically developing children). They found the rates for any autoimmune disorder for 
both mothers and fathers combined was 22.4% for parents of controls and 30.9% for parents 
of children with PDDs which was not significantly different.  
It is hypothesised that autoimmune disease in autism may lead to neurodevelopmental 
damage. Autoantibodies against proteins associated with the central nervous system (CNS) 
has been reported in some children with autism (Singh et al. 1988; Plioplys et al. 1994; 
Vojdani et al. 2004). In recent studies, antibodies against the fetal brain have been detected 
in some mothers of children with autism; these antibodies have the ability to alter 
behavioural outcomes in the offspring of animal models (Enstrom et al. 2009). 
A review by Theoharides et al (2008) proposes a relationship between GI factors, oxidative 
stress and immune dysregulation and proposes potential drug targets in autism.  
4.1.4.3 Vaccination and autism 
Although an array of epidemiological studies do not support causality (DeStefano 2007; 
Baker 2008), the alleged link between autism and vaccination has been debated extensively 
and many parents and parent advocacy groups continue to suspect that vaccines cause 
autism. Putative mechanisms for vaccine associated autism include: “1) immune response 
directed towards a vaccine that cross reacts with host antigens, 2) host response to a vaccine 
that would result in the production of cytokines and a subsequent autoimmune reaction and 
3) toxic components of a vaccine that directly impact on the immune or nervous system” 
(Levy&Hyman 2005, p.134). 
Therefore as outlined in Table 2, immune dysfunction in autism provides a rationale for the 
use of CAM products that are claimed to be immunomodulators/immunoadjuvants and 
include: vitamin A, DMG, vitamin C, zinc, colostrum and glutamine. 
4.1.5 Normalise neurotransmitters and neurotransmitter metabolites 
Many studies (Young et al. 1978; Garnier et al. 1986; Launay et al. 1987; Minderaa et al. 
1987; Barthelemy et al. 1988; Garreau et al. 1988; Barthelemy et al. 1989; Minderaa et al. 
1989; Martineau et al. 1991; Martineau et al. 1992; Herault et al. 1993; Martineau et al. 
1994; Minderaa et al. 1994; Herault et al. 1996; Croonenberghs et al. 2000; Mulder et al. 
2005; Mulder et al. 2005; Mulder et al. 2009) have focused on neurotransmitter 
abnormalities in individuals with autism. Abnormalities in various neurotransmitters 
have been implicated in the development of autism, including serotonin (5-
hydroxytryptamine, 5-HT), dopamine (DA), noradrenaline (NA), gamma-aminobutryic 
acid, glutamate and neuropeptides.  
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4.1.5.1 Serotonin and metabolites 
5-HT is a monoamine neurotransmitter that plays an important role in the developing 
brain by directing both neuronal proliferation and maturation (McDougle et al. 2005). 
CNS 5-HT activity has been involved in a range of physiological functions, such as sleep, 
sensory perception and appetite, which are often disrupted in autism (Young et al. 1982). 
High levels of 5-HT during early development may cause a loss of 5-HT receptors and 
therefore impact on subsequent neuronal development (Whitaker-Azmitia 2001). 
Neuroimaging studies suggest altered developmental regulation of 5-HT synthesis may 
be associated with the pathogenesis of autism (Chugani et al. 1999). Hyperserotonemia 
has been consistently reported in people with autism in more than 25 published studies 
(Lam et al. 2006). 
4.1.5.2 Dopamine and metabolites 
Dopamine (DA) is a catecholamine which acts as a major neurotransmitter in the brain. 
Generally, the dopaminergic system is thought to affect a wide range of functions, including 
cognition and attention (Nieoullon 2002), motor function (Niimi et al. 2009), predictive 
reward signal mechanisms (Schultz 1998) and immunity (Basu&Dasgupta 2000). Some 
animal research has shown that stereotypies and hyperactivity can be induced by increasing 
dopaminergic functioning suggesting dopaminergic neurons may be overactive in autism 
(Miller et al. 2010).  
4.1.5.3 Noradrenaline  
Noradrenaline (NA) is synthesized from DA by dopamine β-hydroxylase and released from 
noradrenergic neurons as well as from the adrenal medulla into the bloodstream. NA plays 
a critical role in attention, the stress response (i.e. the ‘‘fight or flight’’ response), anxiety, 
and memory (Amaral&Sinnamon 1977; Fitzgerald 2009), which are frequently observed to 
be impaired in individuals with autism. Previous studies have shown that measurements of 
NA (i.e. in plasma and urine) are generally well correlated with measurements in the CNS 
(Roy et al. 1988). A range of neurochemical studies have attempted to examine excretion of 
urinary NA and / or adrenaline (A) in individuals with autism compared with controls and 
have yielded inconsistent findings. Three studies found higher levels of NA and/or A in 
autism compared to controls (Barthelemy et al. 1988; Herault  et al. 1993; Martineau  et al. 
1994), while four studies found no differences (Launay et al. 1987; Martineau et al. 1992; 
Minderaa et al. 1994; Croonenberghs et al. 2000).  
Therefore as outlined in Table 2, the range of neurotransmitter abnormalities that have been 
shown to occur in autism provide a rationale for the use of CAM products that are claim to 
normalise neurotransmitter levels and function such as: high dose pyridoxine and 
magnesium, metabolites and co-factors of the transmethylation and trans-sulphuration 
cycles (see Figure 1), vitamin C, zinc and secretin. 
4.1.6 Sleep 
Sleep problems in children with ASD are common with a prevalence of 44-83% in 
comparison to 10-20% of typically developing young children (Wright et al. 2011). Sleep 
difficulties  contribute to significant morbidity in children and to family stress. Melatonin is 
a hormone that is synthesised in the pineal gland from the precursor tryptophan.  Its 
production is light-sensitive, beginning in the early evening and reaching peak levels at 
approximately 3am.  Daytime secretion of melatonin is generally insignificant (Jan et al. 
www.intechopen.com
 
Complementary Medicine Products Used in Autism - Evidence for Rationale 
 
59 
1999).  The main functions of melatonin within the body are the synchronisation of circadian 
rhythm and control of sleep patterns and endocrine secretions (Natural Medicines 
Comprehensive Database 2011).  The suprachiasmatic nucleus of the anterior hypothalamus 
is responsible for the generation of circadian rhythm.  Transmission of light through the 
retina activates this tissue, causing either inhibition or stimulation of melatonin synthesis in 
the pineal gland.  Sleep induction is thought to occur as a result of direct inhibition of the 
‘wakefulness generating system’ by melatonin (Jan  et al. 1999).   
Two studies have suggested a tendency for autistic children to be deficient in the essential 
amino acid tryptophan, a precursor in the biosynthesis of melatonin (D'Eufemia et al. 1995; 
Arnold et al. 2003).  Additionally, Tordjman et al. (2005) found a significantly lower 
excretion rate of 6-sulphatoxymelatonin, the prominent metabolite of melatonin, in children 
with autistic disorder compared to sex and age-matched controls.  These results support the 
above hypothesis that children with autism may have impaired synthesis of melatonin.  
Therefore, in theory, supplementation with melatonin could potentially improve their 
quality of sleep and hence also their daytime behaviour. 
4.1.7 Nutritional deficiencies 
Factors that contribute to nutritional concerns and deficiencies in children with autism are 
summarised by Geraghty et al. (2010) and include sensory processing difficulties, rituals and 
routines and non-compliance behaviours at meal times. Significantly lower levels of nutrients 
in blood, hair, and other tissues have been seen in autistic children including low levels of 
magnesium (Strambi et al. 2006), iron (Latif et al. 2002), zinc (Yorbik et al. 2004), vitamins A, C 
and E, (Ming et al. 2005)  and polyunsaturated  fatty acids (PUFAs) (Vancassel et al. 2001; Bell 
et al. 2004; Meguid et al. 2008). Further, medications prescribed for children with autism may 
have nutrition related adverse effects and restrictive diets that are frequently implemented in 
autism may compromise nutritional intake. As a result, caregivers may elect to implement 
CAM interventions to treat or prevent nutritional deficiencies. 
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CAM product used 
in autism 
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CAM product used 
in autism 
Abnormality 
theorised/reported  to 
occur in autism 
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CAM product used 
in autism 
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CAM product used 
in autism 
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theorised/reported  to 
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Table 2. CAM products used in autism, theoretical or proven abnormality in autism, 
rationale for use and symptom/behaviour targeted 
5. Conclusion 
Available evidence for the theoretical or proven rationale of a range of CAM products has 
been compiled to give researchers and health professionals insight into why such agents are 
recommended and implemented in autism. This information forms the basis for the second 
part of this 2-part review which follows examining the efficacy and safety of a range of 
CAM products used in autism.   
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